TERAZOSIN IN THE CHRONIC TREATMENT OF THE URINARY SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA

Once daily administration of between 1 mg and 20 mg of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetraydro-2-furanyl)carbonyl]piperazine (terazosin) or a pharmaceutically acceptable salt thereof provides a safe and effective means for the chronic treatment of the urinary symptoms associated with...

Full description

Saved in:
Bibliographic Details
Main Authors GLASSMAN HARRIET N, LUTHER ROBERT R, JORDAN DAVID C, LEPOR HERBERT
Format Patent
LanguageEnglish
Published 03.01.2002
Edition7
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Once daily administration of between 1 mg and 20 mg of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetraydro-2-furanyl)carbonyl]piperazine (terazosin) or a pharmaceutically acceptable salt thereof provides a safe and effective means for the chronic treatment of the urinary symptoms associated with benign prostatic hyperplasia. Treatment with terazosin resulted in about 43% reduction in symptoms and a 26% increase in peak urine flow rates compared with baseline.
Bibliography:Application Number: US19930068878